Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2026 | 03-2025 | 03-2024 | 03-2023 | 03-2022 | |
| Sales | 14,119,020 | 12,749,000 | 10,620,000 | 11,418,000 | 10,624,000 |
| Cost of Goods | 2,695,612 | 2,328,000 | 1,937,000 | 2,168,000 | 2,074,000 |
| Gross Profit | 11,423,410 | 10,421,000 | 8,683,000 | 9,250,000 | 8,550,000 |
| Operating Expenses | 8,898,650 | 10,147,000 | 8,513,000 | 8,250,000 | 7,274,000 |
| Operating Income | 2,525,378 | 274,000 | 169,000 | 1,000,000 | 1,276,000 |
| Interest Expense | 92,875 | 118,000 | 80,000 | 66,000 | 41,000 |
| Other Income | 52,971 | 52,000 | 76,000 | 61,000 | 51,000 |
| Pre-tax Income | 2,485,474 | 208,000 | 165,000 | 995,000 | 1,286,000 |
| Income Tax | 561,086 | -130,000 | 52,000 | 253,000 | 269,000 |
| Net Income Continuous | 1,924,388 | 338,000 | 113,000 | 742,000 | 1,017,000 |
| Minority Interests | 264 | N/A | N/A | N/A | N/A |
| Net Income | $1,924,131 | $338,000 | $113,000 | $742,000 | $1,017,000 |
| EPS Basic Total Ops | 1.07 | 0.19 | 0.06 | 0.41 | 0.55 |
| EPS Basic Continuous Ops | 1.07 | 0.19 | 0.06 | 0.41 | 0.55 |
| EPS Diluted Total Ops | 1.07 | 0.19 | 0.06 | 0.41 | 0.55 |
| EPS Diluted Continuous Ops | 1.07 | 0.19 | 0.06 | 0.41 | 0.55 |
| EPS Diluted Before Non-Recurring Items | 1.57 | 1.09 | 0.58 | 0.91 | 0.60 |
| EBITDA(a) | $3,809,691 | $1,602,000 | $1,215,000 | $1,795,000 | $1,929,000 |